Key result
Venlafaxine use in a 43-year-old male with Parkinson disease on dopaminergic therapy induced serotonin syndrome, severe rhabdomyolysis, and acute renal failure.
Case Report (n=1)
Venlafaxine may cause severe serotonin syndrome with rhabdomyolysis and acute renal failure in patients with Parkinson disease on dopaminergic therapy.
May warrant caution with venlafaxine plus dopaminergic therapy in Parkinson disease; leaves open need for systematic safety data.
A 43-year-old male patient with idiopathic Parkinson disease, on dopaminergic therapy, was admitted with confusion and agitation, diaphoresis, and hyperkinesia after the commencement of the serotonin-noradrenaline reuptake inhibitor venlafaxine 2 weeks prior for depression. He was found to have severe rhabdomyolysis and developed acute renal failure. The most likely diagnosis was serotonin syndrome induced by venlafaxine, although neuroleptic malignant syndrome was also considered. The differential diagnosis, atypical features in this presentation, and possible mechanisms are discussed.
No takes yet. Share an insight, caveat, or question.
Rajapakse et al. (2010) conducted a case report in Idiopathic Parkinson disease (n=1). Venlafaxine was evaluated on Serotonin syndrome, severe rhabdomyolysis, and acute renal failure. Venlafaxine use in a 43-year-old male with Parkinson disease on dopaminergic therapy induced serotonin syndrome, severe rhabdomyolysis, and acute renal failure.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: